Skip to main content

Advertisement

Table 1 Patient characteristics by anlotinib dose cohort

From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Characteristic Number of patients
Four consecutive weeks 2-week on/1-week off
5 mg/person 10 mg/person 10 mg/person 12 mg/person 16 mg/person
Total   4 4 3 21 3
 Sex Male 2 2 2 15 1
Female 2 2 1 6 2
 Age, year Median 39 50 60 47 45
Range 21–49 39–60 53–65 32–60 48–55
 ECOG score 0 0 1 0 9 0
1 4 3 3 12 3
 Pretreatment Surgery 3 4 2 18 2
Radiotherapy 2 1 3 6 1
Chemotherapy 4 4 3 15 3
 Tumor site Sarcoma 2 1 1 4 1
MTC 0 0 0 6 0
CC 1 2 0 0 1
NSCLC 0 0 1 3 0
RC 0 0 0 4 0
Other 1 1 1 4 1
  1. ECOG Eastern Cooperative Oncology Group, MTC medullary thyroid carcinoma, CC colorectal carcinoma, NSCLC non-small cell lung cancer, RC renal carcinoma